CRL
Charles River Laboratories International·NYSE
--
--(--)
--
--(--)
CRL fundamentals
Charles River Laboratories International (CRL) released its earnings on Feb 18, 2026: revenue was 994.23M (YoY -0.83%), beat estimates; EPS was 2.39 (YoY -10.15%), beat estimates.
Revenue / YoY
994.23M
-0.83%
EPS / YoY
2.39
-10.15%
Report date
Feb 18, 2026
CRL Earnings Call Summary for Q4,2025
- Revenue and Margin: 2026 guidance for flat to -1% organic revenue growth, with non-GAAP EPS $10.70-$11.20 (+4%-9% YoY). Operating margin to expand 20-50 bps YoY.
- Strategic Acquisitions: K.F. (Cambodia) to reduce NHP costs, PathoQuest to enhance biologics testing. Divestitures expected to complete by mid-2026.
- Demand Trends: DSA net book-to-bill 1.12x in Q4, with cautious optimism for H2 2026 growth. Biotech funding rebounded to $28B in Q4.
- Q1 Challenges: Mid-teens operating margin due to NHP timing, stock comp costs, and higher DSA sourcing expenses.
- AI and NAMs: Long-term focus on NAMs as incremental tools, with Retrogenix and virtual control groups driving efficiency.
- Leadership Transition: Birgit Girshick to succeed Jim Foster as CEO, with seamless transition planned.
EPS
Actual | 1.84 | 1.58 | 2.33 | 2.39 | 2.53 | 2.61 | 2.7 | 2.49 | 2.75 | 2.77 | 2.63 | 2.98 | 2.78 | 2.69 | 2.72 | 2.46 | 2.27 | 2.8 | 2.59 | 2.66 | 2.34 | 3.12 | 2.43 | 2.39 | |||||||||||
Forecast | 1.493 | 1.2636 | 1.7988 | 2.1086 | 2.1897 | 2.3803 | 2.5842 | 2.432 | 2.7178 | 2.7382 | 2.5025 | 2.7452 | 2.5884 | 2.6384 | 2.3571 | 2.4019 | 2.0649 | 2.3941 | 2.4227 | 2.5276 | 2.0757 | 2.5023 | 2.3377 | 2.3436 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +23.24% | +25.04% | +29.53% | +13.35% | +15.54% | +9.65% | +4.48% | +2.38% | +1.18% | +1.16% | +5.09% | +8.55% | +7.40% | +1.96% | +15.40% | +2.42% | +9.93% | +16.95% | +6.91% | +5.24% | +12.73% | +24.69% | +3.95% | +1.98% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 707.06M | 682.58M | 743.30M | 790.99M | 824.57M | 914.61M | 895.94M | 905.05M | 913.93M | 973.13M | 989.16M | 1.10B | 1.03B | 1.06B | 1.03B | 1.01B | 1.01B | 1.03B | 1.01B | 1.00B | 984.17M | 1.03B | 1.00B | 994.23M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 692.23M | 638.13M | 716.88M | 756.86M | 798.20M | 880.72M | 906.90M | 888.27M | 910.10M | 995.18M | 970.43M | 1.04B | 986.31M | 1.05B | 1.00B | 991.25M | 992.31M | 1.02B | 975.99M | 983.63M | 941.97M | 985.24M | 990.82M | 986.70M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +2.14% | +6.97% | +3.69% | +4.51% | +3.30% | +3.85% | -1.21% | +1.89% | +0.42% | -2.22% | +1.93% | +6.26% | +4.37% | +0.59% | +2.61% | +2.24% | +1.94% | +0.17% | +3.46% | +1.92% | +4.48% | +4.76% | +1.42% | +0.76% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for Charles River Laboratories International next quarter?What does Charles River Laboratories International do and what are its main business segments?Did Charles River Laboratories International beat or miss consensus estimates last quarter?What guidance did Charles River Laboratories International's management provide for the next earnings period?What were the key takeaways from Charles River Laboratories International's earnings call?What factors drove the changes in Charles River Laboratories International's revenue and profit?What were the key takeaways from Charles River Laboratories International’s earnings call?What is Charles River Laboratories International's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
